Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
Received 4 January 2017
Accepted for publication 13 March 2017
Published 19 April 2017 Volume 2017:11 Pages 1267—1272
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Tuo Deng
Marilita M Moschos,1,2 Giannis A Moustafa,1 Vasiliki D Papakonstantinou,3 Michael Tsatsos,4 Konstantinos Laios,1 Smaragdi Antonopoulou3
11st Department of Ophthalmology, Medical School, University of Athens, Athens, Greece; 2Biomedical Research Foundation, Academy of Athens, Athens, Greece; 3Laboratory of Biology, Biochemistry, Physiology and Microbiology, Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece; 4Royal Eye Infirmary, Dorset County Hospital NHS Foundation Trust, Dorchester, UK
Purpose: Altered platelet aggregability has been implicated in the pathogenesis of glaucoma. This study aims to investigate the anti-platelet potential of intraocular pressure lowering drops, with the possibility of establishing it as an additional mechanism of anti-glaucomatous action.
Materials and methods: The anti-aggregating effects of a series of anti-glaucomatous eye drops were determined on human platelets in the platelet aggregation model, using four known aggregating factors (platelet activating factor [PAF], adenosine diphosphate [ADP], thrombin receptor-activating peptide [TRAP], and arachidonic acid [AA]).
Results: Almost all of the tested samples inhibited platelet aggregation induced by PAF, ADP, TRAP, and AA, except for Alphagan, which did not demonstrate inhibition of ADP- and TRAP-induced aggregation at a wide range of concentrations. Trusopt, Betoptic, and Azarga eye drops were the most potent inhibitors of all four aggregating factors, while Alphagan was the least potent (P<0.05).
Conclusion: This study shows that anti-glaucomatous eye drops possess anti-platelet effects, and this was shown for the first time by experimenting on human platelets.
Keywords: glaucoma, eye, platelet, aggregation, PAF, TRAP
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]